HLB Gains FDA Approval for Anticancer Drug 'Lirafugratinib (Lyfigo)'… Enters U.S. Commercialization as a Bile Duct Cancer Treatment
With the U.S. Food and Drug Administration (FDA) approving its new anticancer drug, HLB has officially entered the global new drug commercialization stage. ▲ FDA Approval for 'Lyfigo' as a Bile Duct Cancer Treatment On the 23rd, the U.S. FDA approved 'Lyfigo' (ingredient name: lirafugratinib), an

With the U.S. Food and Drug Administration (FDA) approving its new anticancer drug, HLB has officially entered the global new drug commercialization stage.
▲ FDA Approval for 'Lyfigo' as a Bile Duct Cancer Treatment
On the 23rd, the U.S. FDA approved 'Lyfigo' (ingredient name: lirafugratinib), an FGFR2-targeted anticancer drug developed by Elevar Therapeutics, HLB's U.S. subsidiary, for the treatment of adult patients with unresectable locally advanced or metastatic bile duct cancer (cholangiocarcinoma) with FGFR2 fusions or other rearrangements who have previously received treatment. Lyfigo is an oral kinase inhibitor targeting FGFR2.
With this approval, HLB now holds an FDA-approved anticancer new drug, expanding its business from new drug development into the commercialization stage in the U.S. market.
▲ Based on REFOCUS Trial Results… Confirmed Objective Response Rate of 46%
The FDA approval was based on the results of REFOCUS, a multicenter, open-label, single-arm clinical trial. According to the FDA, 116 patients with unresectable or metastatic bile duct cancer participated in the trial. They had previously received chemotherapy or chemoimmunotherapy and had no prior experience with FGFR inhibitor treatment.
According to the clinical results released by Elevar, the confirmed objective response rate (ORR) was 46%, and the median duration of response (mDOR) was 11.8 months.
▲ U.S. Launch in Q4 2026… European Approval and Indication Expansion in Parallel
Commercialization plans are now underway in earnest. Elevar plans to launch Lyfigo in the U.S. market in the fourth quarter of 2026. The company is also pursuing European approval procedures and development to expand the indication to other solid tumors with confirmed FGFR2 fusions or rearrangements.
The key significance of this approval is that the new drug has moved beyond the clinical development stage into the actual sales stage. Going forward, key variables for assessing HLB's global anticancer drug business outlook are expected to include the timing of the U.S. launch, the pace of prescription uptake, progress on European approval, and clinical results for additional indications.
[This article is an informational piece based on materials released by the FDA and the company, and does not recommend buying or selling any specific stock. A new drug's market performance and corporate value may vary depending on sales results, approval scope, and clinical outcomes, and responsibility for investment losses lies with the investor. AI was used for some sentence structuring and data organization.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.


![[Breaking] Evernos Holdings (XRPN) Flat at $7.45... Bitcoin at $64,922, Market on Alert Over Weakness in Leading Stock](/_next/image?url=https%3A%2F%2Fmedia.cbcglobe.com%2Ftenants%2Fcbc00000-0000-4000-8000-000000000001%2Fmedia%2Fcbc%2F2026%2F11%2F626848%2F4c15339f3668573e%2Fvariants%2Fhero.webp&w=1920&q=75)
